Completed PHASE2 INTERVENTIONAL NCT00470171

Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis (URSONASH)

Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis

Sponsor: Axcan Pharma

Conditions Serum Levels of ALAT Transaminases Serum Markers for Fibrosis and Hepatic Inflammation

Updated 5 times since 2017 Last updated: Feb 2, 2009 Started: Oct 31, 2005 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00470171, this PHASE2 trial focuses on Serum Levels of ALAT Transaminases and Serum Markers for Fibrosis and Hepatic Inflammation and remains completed. Sponsored by Axcan Pharma, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Axcan Pharma

Data source: Axcan Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France